Rachael Lester
Corporate Officer/Principal bij HARPOON THERAPEUTICS, INC.
Oorsprong van het eerstegraads netwerk van Rachael Lester
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Subsidiary | Biotechnology | 26 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Rachael Lester via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Undergraduate Degree Undergraduate Degree | |
| The University of California, San Francisco | College/University | Doctorate Degree Doctorate Degree Corporate Officer/Principal | |
| SEAGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Iterum Therapeutics US Holding Ltd.
 Iterum Therapeutics US Holding Ltd. Financial ConglomeratesFinance Iterum Therapeutics US Holding Ltd. operates as a clinical-stage pharmaceutical company. The company was founded in 2018 and is headquartered in Chicago, IL. | Financial Conglomerates | Director/Board Member Director/Board Member | |
| TURMERIC ACQUISITION CORP. | Financial Conglomerates | Chief Executive Officer Director/Board Member | |
ReCode Therapeutics, Inc.
 ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
| Harvard T.H. Chan School of Public Health | College/University | Graduate Degree Graduate Degree | |
| ASTERIAS BIOTHERAPEUTICS INC | Biotechnology | Director of Finance/CFO Comptroller/Controller/Auditor | |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Biotechnology | Founder Founder | |
Iterum Therapeutics International Ltd.
 Iterum Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Iterum Therapeutics International Ltd. engages in the development of clinical-stage pharmaceutical products. The company was founded in 2015 and is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Biotechnology | Director of Finance/CFO Chief Executive Officer | |
| EXELIXIS, INC. | Pharmaceuticals: Major | General Counsel Chief Tech/Sci/R&D Officer | |
| DYNAVAX TECHNOLOGIES CORPORATION | Biotechnology | Director/Board Member Chairman | |
| ITERUM THERAPEUTICS PLC | Pharmaceuticals: Major | Chairman Director/Board Member | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Founder Private Equity Investor | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder Founder | |
| RAPTOR PHARMACEUTICAL CORP | Pharmaceuticals: Major | Director of Finance/CFO Director of Finance/CFO | |
| Kellogg School of Management | College/University | Masters Business Admin | |
Tourmaline Bio, Inc.
 Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
| Swarthmore College | College/University | Undergraduate Degree | |
| ARRAY TECHNOLOGIES, INC. | Pharmaceuticals: Major | Chief Operating Officer | |
Gene Solutions LLC
 Gene Solutions LLC BiotechnologyHealth Technology Gene Solutions LLC conducts therapeutic drug discovery research for central nervous system diseases by utilizing its proprietary mitochondrial genomic targets. It delivers mitochondrial therapeutic solutions and choices for pharmaceutical and biotechnology companies to enhance their drug pipelines in the field of Alzheimer’s, Parkinson’s, and schizophrenia diseases. The company was founded in 2006 by William Davis Parker Jr. and Edward P Connell and is headquartered in Charlottesville, VA. | Biotechnology | Director/Board Member | |
Serenex, Inc.
 Serenex, Inc. Pharmaceuticals: MajorHealth Technology Serenex, Inc. operates as a biotechnology company that develops drugs for tumors and cancers of the blood and bone marrow. Its products include drugs for chemotherapy treatments as well as inhibitor compounds. Serenex was founded by George Young and Timothy Haystead in 2000 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Founder | |
Waratah Pharmaceuticals, Inc.
 Waratah Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Part of OPKO Health, Inc., Waratah Pharmaceuticals, Inc. develops pharmaceutical products. The company is based in Calgary, Canada. The Canadian company was founded by Susan Dana Jones. Waratah Pharmaceuticals was acquired by Transition Therapeutics, Inc., part of OPKO Health, Inc. from September 01, 2016 on January 28, 2002 for $15.46 million. | Medical Specialties | Founder | |
| HOSPIRA, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Idun Pharmaceuticals, Inc.
 Idun Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Idun Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of human therapeutics to control apoptosis. The company was founded by John C. Reed, Robert H. Horvitz, and Lawrence C. Fritz in March 1993 and is headquartered in San Diego, CA. | Medical Specialties | Director/Board Member | |
| FATE THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| COGENT BIOSCIENCES, INC. | Biotechnology | Chief Executive Officer | |
| PFIZER, INC. | Pharmaceuticals: Major | Chief Operating Officer | |
Convergent Therapeutics, Inc.
 Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | Pharmaceuticals: Major | Chairman | |
| University of California, Davis | College/University | Undergraduate Degree | |
Beal Advisors LLC
 Beal Advisors LLC Investment ManagersFinance Beal Advisors LLC provides investment advice services. The private company is based in Walnut Creek, CA. The company was founded by Georgia L. Erbez. | Investment Managers | Founder | |
| ZOSANO PHARMA CORPORATION | Pharmaceuticals: Major | Director of Finance/CFO | |
| REVOLUTION MEDICINES, INC. | Pharmaceuticals: Other | Director of Finance/CFO | |
Jefferies LLC
 Jefferies LLC Investment Banks/BrokersFinance Jefferies LLC is a global investment bank and institutional securities firm headquartered in New York City. The firm was founded in 1962 and is a subsidiary of Jefferies Group LLC, ultimately held by Jefferies Financial Group, Inc. (NYSE: JEF). Jefferies provides corporate clients with research and execution services in equity, fixed income, and foreign exchange markets, as well as a full range of investment banking services such as underwriting, mergers and acquisitions, restructuring and recapitalization, and other advisory services, with all businesses operating in the Americas, Europe and Asia. | Investment Banks/Brokers | Corporate Officer/Principal | |
ImmuRx, Inc.
 ImmuRx, Inc. BiotechnologyHealth Technology ImmuRx, Inc. develops adjuvant platforms for the treatment of cancer and infectious disease. Its product includes CD40 compound, an antibody. The company was founded by Randolph J. Noelle and Ross Kedl in 2005 and is headquartered in Lebanon, NH. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| UCB | Pharmaceuticals: Major | Corporate Officer/Principal | |
Shearman & Sterling LLP
 Shearman & Sterling LLP Miscellaneous Commercial ServicesCommercial Services Shearman & Sterling LLP provides legal services. It specializes in appellate litigations, capital markets, corporate governance, environmental, finance, international arbitration, investment funds, litigation, mergers and acquisitions, privatization, real estate, and tax. The company was founded by Thomas Shearman in 1873 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Discovery Channel
 Discovery Channel BroadcastingConsumer Services Part of Warner Bros. The company is based in Bethesda, MD. Discovery, Inc., Discovery Channel is a provider of television broadcasting services. | Broadcasting | Corporate Officer/Principal |
Statistieken
Internationaal
| Verenigde Staten | 45 |
| Ierland | 3 |
| Canada | 2 |
| België | 2 |
Sectoraal
| Health Technology | 32 |
| Consumer Services | 9 |
| Finance | 7 |
| Commercial Services | 4 |
Operationeel
| Director/Board Member | 139 |
| Corporate Officer/Principal | 63 |
| Independent Dir/Board Member | 50 |
| Chief Tech/Sci/R&D Officer | 24 |
| Undergraduate Degree | 23 |
Sterkste connecties
| Insiders | |
|---|---|
| Luke Evnin | 42 |
| Alan Colowick | 30 |
| Ron Hunt | 29 |
| Mark Chin | 25 |
| Patrick Baeuerle | 19 |
| Scott Myers | 18 |
| Joanne Viney | 18 |
| Georgia Erbez | 18 |
| Julia Eastland | 16 |
| Lauren Silvernail | 14 |
| Gerald McMahon | 13 |
| Natalie Sacks | 13 |
| Joseph Bailes | 12 |
| Andrew Robbins | 11 |
| Jonathan Drachman | 10 |
- Beurs
- Insiders
- Rachael Lester
- Bedrijfsconnecties
